Is Synlogic Inc (SYBX) Stock About to Get Hot Thursday?

Synlogic Inc (SYBX) stock is lower by 48.41% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Synlogic Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SYBX!

See Full SYBX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With SYBX Stock Today?

Synlogic Inc (SYBX) stock is unchanged 0% while the S&P 500 has gained 0.51% as of 3:22 PM on Thursday, Feb 15. SYBX is unmoved $0.00 from the previous closing price of $1.78 on volume of 119,635 shares. Over the past year the S&P 500 has risen 21.52% while SYBX is down -85.53%. SYBX lost -$12.72 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Synlogic Inc click here.

More About Synlogic Inc

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects. Click Here to get the full Stock Report for Synlogic Inc stock.